Algorae Pharmaceuticals Ltd (PK) (LVCLF) Cotización

Living Cell Technologies Limited changed to Algorae Pharmaceuticals Ltd

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

WoW this place is Dead... Good opportunity for a Maytag repairperson

LVCLY Daily Chart

News out: LCT extends cash runway with receipt from Vertex acquisition

Link:
https://www.otcmarkets.com/stock/LVCLY/news/LCT-extends-cash-runway-with-receipt-from-Vertex-acquisition?id=243331



October 15, 2019
OTC Disclosure & News Service

Auckland, New Zealand —

This release includes additional documents. Select the link(s) below to view.
191015 LCT extends cash runway with receipt from Vertex acquisition of Semma.pdf

What's Up??? Hmmmn

https://finance.yahoo.com/news/owns-most-living-cell-technologies-010514215.html

The big shareholder groups in Living Cell Technologies Limited (ASX:LCT) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to<div><a class="permalink" href="

Pig hearts could soon be tested in humans after scientists pass important milestone

telegraph.co.uk

Pig hearts could soon be tested in humans after scientists passed an important milestone when transplanting the organs into primates.

In 2000, the International Society for Heart and Lung Transplantation (ISHLT)suggested that human trials would be considered once 60 per cent of primates could live for three months, with at least some indication that longer survival was possible.

Previous studies have only achieved up to 57 days survival, so the new research is the first to meet the criteria set out by the ISHLT, and represents a major step in the clinical use of pig hearts in humans.

Now surgeons in Germany, using hearts from pigs that had been genetically modified to remove threatening viruses...

Click...click...click

Piggies getting restless??? Hopefully good news and back to the +$1.00 world.... Peace

Did I just hear an Oink Oink.??? Got piggies Go!!

Hahaha sorry wrong board ontgis last post

Yoda for mod has my vote. New to crypto and he offered excellent advise to help get me setup to make my first purchase. I was having difficulty with some wallets that wouldn’t accept usd or I had to setup wore transfers. Now I’m on one I can fund ripple directly from my checking account and can lock in my rate right at time of purchase regardless of how long the transfer takes. I am not day trading this so just looking for convenience to add when I can and will hold for many years

Believe you have a great entry point. Good luck to all. Peace SJO

I bought into this at 0.18. Not many times that it has dipped below there. I think bottomed our and will only move up from here on next development.

Hmmm appears the Little pigs are getting restless....good news that this play is not dead....
SJO

Decent volume. I think if you can get in on this 0.18 this will only go up from there. 0.17 has been holding up for months. I think it is just waiting for next move by the company. Holding nicely at this price until news.

I think after the market reaction to nov 2017 results it has stabilized around this level now for half a year. Financing is already secured to operate 3 more years. They are starting to become more transparent with regular updates. They are cutting the fat by reducing cost this last quarter. I think we slowly start to move back up again as they continue to analyze results and potentially start a new product or path of research.

Hopefully, good timing on your part. 18 month results due out in Sept or Oct. I had sold half my shares when six month results came out but now am fully loaded. Best of luck to you.

Back in this tiday

Good news for LVCLY. From latest PR:

"The one year follow up of the 18 patients in the Phase IIb study of NTCELL® for Parkinson’s disease shows a statistically significant improvement change in the Unified Parkinson’s Disease Rating Scale (UPDRS Part III in the off state) in the patients who received 40 or 80 NTCELL capsules implantation to the putamen on both sides of the brain as compared to the placebo group that received sham surgery..The Data Safety Monitoring Board has advised that there are no safety issues arising from the data."

Do you still follow lvcly? Price seems to have leveled off here and could start to move back up on next venture

Big spread on bid and ask. The slightest volume makes for big movement. I just hope they get the ball rolling in the right direction again for 2018. Price has finished adjusting accordingly and it’s time to make new positions here

Yes we see potential for it to move on little volume.

I’m hoping the dust has settled and made my entry today. I heard the results were disappointing in November but it looks like pps has adjusted accordingly and hopefully as updates come out on next move we start to head back up. I’m not going to pretend to know a lot but they just secured 3 million from a sale and exclusive rights to diabecell in a few countries to be used in other products in their pipeline such as pericyte protective agents. I guess first stop FDA approval, then find a positive result.......

LVCLY buy 0.2050

stochastics crossing up from oversold
macd, rsi, and stochastics bullish divergence
about to cross up over an extended moving average
bollinger bands squeezed so a volatile move pending

normal chart




log chart

http://www.lctglobal.com/upload/news/2017/171115%20Chairmans%20Address%202017%20AGM.pdf

Yeah, tough results I just did not see coming. Bad news for my account but worse news for those with Parkinson's....

Shucks....:+(

Results coming in soon. Very interested to see how this plays out. Hoping for the best, not only because of my account balance but for those suffering from Parkinson's. Good luck to you...

NTCELL Clinical Study results to be announced on Friday 10 November

Results of NTCELL® Clinical Study in Parkinson’s 

Results released to ASX on Friday 10 November

Company to host conference call on Friday 10 November at 2:00pm AEST / 4:00pm NZT

LCT has announced a trading halt ahead of the announcement of the results of the Phase IIb clinical study of NTCELL in Parkinson's disease on Friday 10 November. 

Investor call

LCT CEO Ken Taylor and Principal Investigator Dr Barry Snow will host an investor call to discuss the results of the Phase IIb clinical study of NTCELL in Parkinson's disease on the day of the announcement.

Date: Friday 10 November 2017
Time: NZT 4:00pm, AEST 2:00pm 

Conference ID: 3389168

Toll-free dial-in numbers for participants:
Australia - 1800 123 296
New Zealand - 0800 452 782
Canada - 1855 5616 766
China - 4001 203 085
Hong - Kong 800 908 865
India - 1800 3010 6141
Japan - 0120 985 190
Singapore - 800 616 2288
United Kingdom - 0808 234 0757
United States - 1855 293 1544
or
toll +61 2 8038 5221

?

NTCELL Clinical Study results to be announced on Friday 10 November

Results of NTCELL® Clinical Study in Parkinson’s 

Results released to ASX on Friday 10 November

Company to host conference call on Friday 10 November at 2:00pm AEST / 4:00pm NZT

LCT has announced a trading halt ahead of the announcement of the results of the Phase IIb clinical study of NTCELL in Parkinson's disease on Friday 10 November. 

Investor call

LCT CEO Ken Taylor and Principal Investigator Dr Barry Snow will host an investor call to discuss the results of the Phase IIb clinical study of NTCELL in Parkinson's disease on the day of the announcement.

Date: Friday 10 November 2017
Time: NZT 4:00pm, AEST 2:00pm 

Conference ID: 3389168

Toll-free dial-in numbers for participants:
Australia - 1800 123 296
New Zealand - 0800 452 782
Canada - 1855 5616 766
China - 4001 203 085
Hong - Kong 800 908 865
India - 1800 3010 6141
Japan - 0120 985 190
Singapore - 800 616 2288
United Kingdom - 0808 234 0757
United States - 1855 293 1544
or
toll +61 2 8038 5221

Meet the animal scientist trying to grow human organs — in pigs. https://tiny.iavian.net/joyv

Living Cell Technologies: Impending Phase IIb Results For NTCELL, A Disease-Modifying Agent For Parkinson's https://seekingalpha.com/article/4109231?source=ansh $LVCLY, $ACAD

NOVEMBER as Trial data released...love them Pigs... Peace. SJO

When will a news announcement be coming re status of LVCLY?

Long live the Auckland herd!!!

Holy Pig Skins Batman. $3.00 by Holloween.. ? Trick or Treat or Buy Out...????

Tic...Tic...Tic...

Any speculation on pop over $2.00 after November test results released?? My quess there will be a nice buy out offer from a Big Pharma Company.

Peace
SJO

Loving it! Hope it continues right on up to trial results in November. I'm letting my shares ride for a while....

$1.52 mid day... News coming??

Amen,. It's been a long wait.... Peace. SJO

Looks likely. Talk about being under the radar. Current market cap of $75 million. If the results hold in November and shows procedure continues to turn back Parkinson's, share price should move up considerably.

Do I smell $1.50 by holloween? IMMINENT.. ???

MAYbe...

Trial results coming up in November. Hoping they are similar to early results, which were absolutely amazing. Hard to find a lot of info on this company. I would urge anybody interested in investing here to go to their website and subscribe to their emails, which keep you up to date on what is going on...

Break the $1.00 ceiling soon....

Hmmmmm....... MAYbe

Peace

SJO

Under the radar play right here

Pump. Pump. Pum..Pump it up

Acorda Therapeutics.

Also, Cramer checked in with Dr. Ron Cohen, the founder and CEO of Acorda Therapeutics. "In this increasingly difficult market, I think it's worth circling the wagons around secular growth companies, like the biotechs, because they're not sensitive to swings in the global economy," Cramer said.

And with Acorda Therapeutics (ACOR) buying the privately held Civitas Therapeutics for $525 million, Cramer felt the company deserved a closer look.
"Through the acquisition, Acorda will get a promising inhaled dry powder formulation that helps alleviate some of the symptoms of Parkinson's disease. Not only does this drug address a real unmet medical need, but it's right on the cusp of entering phase 3 trials and it could potentially do $500 million in peak sales. If this drug can get FDA approval then Civitas will look like a total steal. But if it gets bottled up because of weak phase 3 results, it might be a colossal overpay."


Cramers Comments of Parkinson

GREAT INFO..Thanks for the post... Lonely HERE today BUT SOMEDAY MAYbe no so much...

Other Day there was feature on CNBC about some Company that has a "new" Parkinson Treatment via a lung Inhaler... Treatment looked interesting BUT discuss on how the FDA "frowns" on drug delivery via the lungs..


I LOVE OUR PIGS.... !!!!

SJO